TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.

TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
复制标题

DOI:
10.18632/oncotarget.8525
复制
发表时间:
2016-05-31
期刊:
影响因子:
--
通讯作者:
Cai X
Cai X
中科院分区:
其他
文献类型:
--
作者:
Shen J;Lin H;Li G;Jin RA;Shi L;Chen M;Chang C;Cai X

文献摘要

参考文献

被引文献

相似文献

早期研究表明TR 4核受体(TR 4)可能在调节前列腺癌进展中起关键作用,但其与肝癌进展的潜在联系尚不清楚。在这里,我们发现肝细胞癌(HCC)细胞中TR 4的高表达可能会增强顺铂化疗的疗效,以更好地抑制HCC的进展。用TR 4-siRNA敲低HCC Huh 7和Hep 3B细胞中的TR 4增加顺铂化疗耐药性,并且在HCC LM 3和SNU 387细胞中过表达TR 4和TR 4-cDNA增加顺铂化疗敏感性。机制研究发现TR 4可能通过在转录水平上改变ATF 3的表达而增强顺铂化疗敏感性,ATF 3-siRNA阻断ATF 3表达可逆转TR 4增强的肝癌细胞顺铂化疗敏感性。使用异种移植的HCC LM 3细胞的体内HCC小鼠模型也证实了显示TR 4增强顺铂化疗敏感性的体外细胞系数据。总之,这些结果提供了一种新的潜在治疗方法,通过改变TR 4-ATF 3信号来增加顺铂的疗效,从而更好地抑制HCC进展。
Early studies indicated that TR4 nuclear receptor (TR4) may play a key role to modulate the prostate cancer progression, its potential linkage to liver cancer progression, however, remains unclear. Here we found that higher TR4 expression in hepatocellular carcinoma (HCC) cells might enhance the efficacy of cisplatin chemotherapy to better suppress the HCC progression. Knocking down TR4 with TR4-siRNA in HCC Huh7 and Hep3B cells increased cisplatin chemotherapy resistance and overexpression of TR4 with TR4-cDNA in HCC LM3 and SNU387 cells increased cisplatin chemotherapy sensitivity. Mechanism dissection found that TR4 might function through altering the ATF3 expression at the transcriptional level to enhance the cisplatin chemotherapy sensitivity, and interrupting ATF3 expression via ATF3-siRNA reversed TR4-enhanced cisplatin chemotherapy sensitivity in HCC cells. The in vivo HCC mouse model using xenografted HCC LM3 cells also confirmed in vitro cell lines data showing TR4 enhanced the cisplatin chemotherapy sensitivity. Together, these results provided a new potential therapeutic approach via altering the TR4-ATF3 signals to increase the efficacy of cisplatin to better suppress the HCC progression.
DOI: 10.1073/pnas.91.13.6040
发表时间: 1994-06-21
影响因子: 11.1
作者:
CHANG, CS;DASILVA, SL;BURBACH, JPH
通讯作者: BURBACH, JPH
DOI: 10.3322/canjclin.55.2.74
发表时间: 2005-03-01
影响因子: 254.7
作者:
Parkin, DM;Bray, F;Pisani, P
通讯作者: Pisani, P
DOI: 10.1016/j.bbrc.2007.06.168
发表时间: 2007-09-21
影响因子: 3.1
作者:
Kim, Eungseok;Ma, Wen-Lung;Chang, Chawnshang
通讯作者: Chang, Chawnshang
DOI: 10.2337/db10-0628
发表时间: 2011-01
期刊: Diabetes
影响因子: 7.7
作者:
Kang HS;Okamoto K;Kim YS;Takeda Y;Bortner CD;Dang H;Wada T;Xie W;Yang XP;Liao G;Jetten AM
通讯作者: Jetten AM
DOI: 10.2337/db10-0393
发表时间: 2011-05
期刊: Diabetes
影响因子: 7.7
作者:
Kim E;Liu NC;Yu IC;Lin HY;Lee YF;Sparks JD;Chen LM;Chang C
通讯作者: Chang C